Diabetes drug revenue

In 3Q17, Merck’s (MRK) Januvia generated revenue of ~$1.0 billion which reflected ~1% growth YoY (year-over-year) and ~7% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Januvia generated revenue of ~$2.8 billion.

In 3Q17, Janumet reported revenue of $513 million, which reflected a ~6% fall YoY and a 9% fall QoQ. In September 2017, Janumet had generated YTD (year-to-date) revenue of $1.57 billion, compared with $1.62 billion YTD in September 2016. Pricing pressure primarily contributed to the modest decline of Januvia and Janumet revenue, partially offset by global volume growth.

Januvia (sitagliptin) is used for the treatment of individuals with type 2 diabetes. In the marketplace, Januvia competes with Novo Nordisk’s (NVO) Victoza, AstraZeneca’s (AZN) Onglyza, and Novartis’s (NVS) Galvus. In 3Q17, Victoza, Onglyza, and Galvus reported revenue of 5.3 billion Danish kroner, $127 million, and $310 million, respectively.

Merck: Diabetes, General Medicine, and Women’s Health after 3Q17

General medicine and women’s health revenue

In 3Q17, Merck’s NuvaRing generated revenue of $214 million, which is ~10% growth YoY and ~8% growth QoQ. In 3Q17, NuvaRing revenue witnessed a ~2% favorable effect of foreign exchange. Higher sales and pricing in the US market also propelled revenue growth.

In 3Q17, Implanon and Nexplanon generated revenue of $155 million, which is ~5% growth YoY and a 13% fall QoQ. Foreign exchange favorably affected Implanon’s revenue by 1% in 3Q17.

In 3Q17, Merck’s Follistim AQ generated revenue of ~$72 million, which reflected ~29% growth YoY. Follistim AQ is used for the treatment of infertility in women who are unable to ovulate. In September 2017, NuvaRing, Implanon, and Follistim AQ reported YTD revenue of $573 million, $503 million, and $232 million, respectively. Merck’s diabetes, general medicine, and women’s health revenue growth could boost the Vanguard Health Care ETF (VHT), of which Merck makes up ~4.2%.

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.